RWJ-67657 (Standard)

RWJ-67657 (Standard) is the analytical standard of RWJ-67657. This product is intended for research and analytical applications. RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity[1].

Product Specifications

CAS Number

[215303-72-3]

UNSPSC

12352100

Target

P38 MAPK; Reference Standards

Related Pathways

MAPK/ERK Pathway; Others

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Smiles

OCCC#CC1=NC(C2=CC=C(F)C=C2)=C(C3=CC=NC=C3)N1CCCC4=CC=CC=C4

Molecular Formula

C27H24FN3O

Molecular Weight

425.50

References & Citations

[1]Shahin R, et al. Research advances in kinase enzymes and inhibitors for cardiovascular disease treatment. Future Sci OA. 2017 Aug 8;3 (4) :FSO204.|[2]Wadsworth SA, et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther. 1999 Nov;291 (2) :680-7.|[3]Frigo DE, et al. p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol. 2006 May;20 (5) :971-83.|[4]Bai YY, et al. Synergistic Effects of Transplanted Endothelial Progenitor Cells and RWJ 67657 in Diabetic Ischemic Stroke Models. Stroke. 2015 Jul;46 (7) :1938-46.